Clinical Trials
98 results for Prostate Cancer
1-50 of 98 Next
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
- Condition: Prostate Cancer
- Study ID: NCT01961713
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pyruvate (13C)
- Study ID: NCT02526368
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
- Condition: Prostate Cancer
- Intervention: Other: Active surveillance
- Study ID: NCT00949819
Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost
- Condition: Prostate Cancer
- Study ID: NCT02016248
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- Condition: Prostatic Neoplasms
- Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
- Study ID: NCT02102477
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Study ID: NCT02643511
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study
- Condition: Locally Advanced and Metastatic Prostate Cancer
- Intervention: Procedure: Radical prostatectomy
- Study ID: NCT02971358
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
- Condition: Prostate Cancer
- Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
- Study ID: NCT01492972
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
- Condition: Prostatic Neoplasms
- Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
- Study ID: NCT01913106
MRI-Guided HDR Brachytherapy for Prostate Cancer
- Condition: Patients With Prostate Cancer
- Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
- Study ID: NCT00913939
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Condition: Prostatic Neoplasms
- Study ID: NCT02861573
Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).
- Condition: Prostatic Neoplasms, Neoplasm Metastasis
- Study ID: NCT02138721
UTSW SBRT Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
- Condition: Cancer Patients Receiving Stereotactic Body RTX
- Intervention: Radiation: SBRT
- Study ID: NCT02170181
Collection of Blood From Patients With Prostate Cancer
- Condition: Prostatic Neoplasms
- Study ID: NCT00923221
Canary Prostate Active Surveillance Study
- Condition: Prostatic Neoplasms
- Study ID: NCT00756665
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Study ID: NCT00588185
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer
- Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
- Study ID: NCT00050752
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
- Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Study ID: NCT00026884
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
- Study ID: NCT00969111
Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition
- Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
- Study ID: NCT01441089
Biospecimen Acquisition From Human Subjects
- Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
- Study ID: NCT00034216
HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields
- Condition: Prostate Cancer
- Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
- Study ID: NCT02918253
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
- Condition: Post Prostatectomy
- Study ID: NCT03160794
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
- Condition: Prostate Cancer
- Intervention: Other: Standard of Care
- Study ID: NCT03151629
Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate
- Condition: Locally Recurrent Prostate Cancer
- Intervention: Radiation: Stereotactic Body Radiotherapy
- Study ID: NCT03073278
The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
- Condition: Prostate Cancer, Cardiovascular Disease
- Study ID: NCT03127631
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
- Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
- Study ID: NCT03678025
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial
- Condition: Prostate Cancer Metastatic
- Study ID: NCT03655886
High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency
- Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
- Intervention: Drug: Testosterone Enanthate
- Study ID: NCT03522064
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Condition: Prostate Cancer
- Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
- Study ID: NCT03574571
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
- Condition: Prostate Cancer, Localized Malignant Neoplasm
- Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Study ID: NCT01766492
A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (fl)
- Condition: Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
- Intervention: Drug: PF-06821497
- Study ID: NCT03460977
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Study ID: NCT03874884
Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSEĀ® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
- Condition: Recurrent Prostate Cancer
- Study ID: NCT03067051
A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
- Condition: Metastatic Castration Resistant Prostate Cancer
- Intervention: Drug: Pembrolizumab
- Study ID: NCT04104893
A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer
- Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
- Study ID: NCT04253483
PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy
- Condition: Recurrent Prostate Cancer
- Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
- Study ID: NCT03718260
ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-Resistant Prostatic Cancer
- Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
- Study ID: NCT03903835
Oligomet-DK. National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
- Condition: Prostate Cancer Metastatic
- Intervention: Procedure: RARP, Radiation: SBRT, Drug: ADT
- Study ID: NCT04086290
Fluciclovine (FACBC) PET/CT Site-Directed Therapy of Oligometastatic Prostate Cancer (Flu-BLAST-PC)
- Condition: Prostate Adenocarcinoma, PSA Level Greater Than or Equal to 0.5, PSA Level Less Than Ten
- Study ID: NCT04175431
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
- Condition: Prostate Cancer
- Study ID: NCT04302454
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer
- Intervention: Drug: REGN5678, Drug: Cemiplimab
- Study ID: NCT03972657
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
- Condition: Oligometastatic Hormone Sensitive Prostate Cancer
- Study ID: NCT04115007
Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan
- Condition: Metastatic Castration-sensitive Prostate Cancer
- Study ID: NCT04601441
68Ga-PSMA-11 PET in Patients With Prostate Cancer
- Condition: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Study ID: NCT04777071
Early Detection of Prostate Cancer by Liquid Biopsy
- Condition: Prostate Cancer
- Study ID: NCT04556916
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
- Condition: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Study ID: NCT04513717
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
- Condition: Biochemically Recurrent Prostate Cancer
- Study ID: NCT05794906
Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04984343
Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
- Condition: Prostate Cancer
- Study ID: NCT05345444